Alnylam Pharmaceuticals (NASDAQ: ALNY) and Vir Biotechnology (NASDAQ: VIR) show no signs of slowing despite the current economic climate. These well-capitalized biotechs have ambitious plans to develop an array of innovative medicines. The companies recently banded together to spearhead a unique approach to attack the novel coronavirus. Let's hope they succeed for society's sake and for the investors willing to risk their hard-earned money to back these COVID-19 fighting biotechs.
With both of these biotechs at the forefront of the most important health issue of our time, which stock is a better buy? Let's find out.
Image source: Getty Images.